Geneva, Switzerland, April 21, 2020 – 7:30am CEST – GeNeuro (Euronext Paris: CH0308403085 – GNRO), a biopharmaceutical company focused on understanding and stopping the causal factors driving the progression of neurodegenerative and autoimmune diseases such as multiple sclerosis , today announces the appointment of the experienced medical and industry professional Prof. David Leppert, MD and Professor of Neurology, as Chief Medical Officer.
https://geneuro.ch/data/news/GeNeuro-PR-CMO-appointment-EN.pdf